| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/12/2009 | US20090068148 Peptides of cav2.2 that inhibit pain |
| 03/12/2009 | US20090068146 Diaryl ureas and combinations |
| 03/12/2009 | US20090068145 Methods and Compositions Relating to Islet Cell Neogenesis |
| 03/12/2009 | US20090068144 Tetrahydro-isoquinolin-1-ones for the treatment of cancer |
| 03/12/2009 | US20090068143 Orally effective cannabinoid analogs |
| 03/12/2009 | US20090068142 Compositions and methods for treating coronavirus infection and sars |
| 03/12/2009 | US20090068141 Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer |
| 03/12/2009 | US20090068140 Hepatitis c virus inhibitors |
| 03/12/2009 | US20090068139 LOOP PEPTIDE AND TGF alpha FOR STIMULATING STEM CELL PROLIFERATION AND MIGRATION |
| 03/12/2009 | US20090068125 Treatment for mucositis |
| 03/12/2009 | US20090068121 Lantibiotics and uses thereof |
| 03/12/2009 | US20090068106 selectively inhibit alpha v beta 3 integrin; used in the treatment of diseases associated with angiogenesis and cancer |
| 03/12/2009 | US20090068103 Aptamers labeled with 68ga |
| 03/12/2009 | US20090068102 Treating stroke |
| 03/12/2009 | US20090068095 Carbonic anhydrase ix (g250) anitbodies and methods of use thereof |
| 03/12/2009 | US20090068094 Inhibitors of endo-exonuclease activity for treating cancer |
| 03/12/2009 | DE202008014557U1 Therapeutische Verwendung Therapeutic use |
| 03/12/2009 | DE102007056231A1 Proteins comprising a Kunitz domain useful as protease inhibitors for therapeutic purposes |
| 03/12/2009 | DE102007043056A1 Use of mannitol-dehydrogenase in medicine, for the therapy or diagnosis of disorder of fructose metabolism including fructose intolerance, to reduce bioavailability of fructose in human or animal and to produce e.g. food additive |
| 03/12/2009 | DE102007042107A1 Pharmaceutical composition, e.g. for tumor therapy, comprises an iron-binding agent coupled to an active ingredient through a peptide linker comprising a protease recognition sequence |
| 03/12/2009 | DE10149678A1 New peptide compounds containing upto 6 aminoacid residues, are potent and specific thrombin inhibitors used for treating and diagnosing diseases associated with thrombin |
| 03/12/2009 | CA2736661A1 Novel fungal enzymes |
| 03/12/2009 | CA2727971A1 Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits |
| 03/12/2009 | CA2711425A1 Antimicrobial activity of bacteriocin-producing lactic acid bacteria |
| 03/12/2009 | CA2698780A1 Use of glp-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission |
| 03/12/2009 | CA2698766A1 Use of gip for the treatment of disorders associated with dysfunctional synaptic transmission |
| 03/12/2009 | CA2698396A1 Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof |
| 03/12/2009 | CA2698357A1 Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
| 03/12/2009 | CA2698173A1 Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof |
| 03/12/2009 | CA2697930A1 Compound for controlling appetite |
| 03/12/2009 | CA2697929A1 Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events |
| 03/12/2009 | CA2697504A1 Salicylanilide modified peptides for use as oral therapeutics |
| 03/12/2009 | CA2697404A1 Method for purifying the factor viii and the von willebrand factor |
| 03/12/2009 | CA2695960A1 Vegfr-1/nrp-1 targeting peptides |
| 03/11/2009 | EP2034023A1 C-C CKR-5 ,CC-Chemikines receptor, derivatives thereof and their uses |
| 03/11/2009 | EP2034015A1 Immunostimulatory oligonucleotide and pharmaceutical application thereof |
| 03/11/2009 | EP2034013A1 Process for the production of bromelain by means of substances that induce proteins in pineapple plants |
| 03/11/2009 | EP2033972A1 Screening method for candidate drugs |
| 03/11/2009 | EP2033970A2 WNT-1 inducible genes |
| 03/11/2009 | EP2033662A1 Transglutaminase mediated conjugation of peptides |
| 03/11/2009 | EP2033661A1 Methods of screening affinity marker libraries |
| 03/11/2009 | EP2033659A2 Inhibitors of complement activation |
| 03/11/2009 | EP2033658A1 Anitbodies to cytokines in the prevention and treatment of inflammatory bowel disease |
| 03/11/2009 | EP2033656A1 Satiety-modulating compositions for oral application |
| 03/11/2009 | EP2033655A1 Use of compounds that inhibit the EF-Tu-nucleolin interaction for preventing or treating tularemia |
| 03/11/2009 | EP2033654A1 Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus |
| 03/11/2009 | EP2033651A1 Oxalate-degrading microorganisms or oxalate-degrading enzymes for preventing oxalate related disease |
| 03/11/2009 | EP2033512A1 Model animal of dendritic cell immunoreceptor gene knockout disease |
| 03/11/2009 | EP2032748A1 Serpine1 polymorphisms are predictive of response to activated protein c administration and risk of death |
| 03/11/2009 | EP2032596A1 Neuroprotective compounds and uses thereof |
| 03/11/2009 | EP2032170A1 Anti-inflammatory composition comprising glycine and lactoferrin and the use thereof |
| 03/11/2009 | EP2032157A1 High frequency application of neurotoxic component of botulinum toxin |
| 03/11/2009 | EP2032155A2 Stabilized insulin-like growth factor polypeptides |
| 03/11/2009 | EP2032154A2 Stabilized insulin-like growth factor polypeptides |
| 03/11/2009 | EP2032153A1 Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma |
| 03/11/2009 | EP2032152A1 Use cathelicidin antimicrobial protein (hcap18 ) as anticancer agent |
| 03/11/2009 | EP2032151A2 Combination therapy method and formulation |
| 03/11/2009 | EP2032150A1 Novel enterococcus and streptococcus strains and bacteriocins |
| 03/11/2009 | EP2032149A2 Method and systems for using biopolymer-based beads and hydrogels |
| 03/11/2009 | EP2032136A1 Compositions and kits comprising a melatonin component and a chondroprotective component |
| 03/11/2009 | EP2031986A1 Induction of tolerance to egg proteins |
| 03/11/2009 | EP1888099A4 Hydratable keratin compositions |
| 03/11/2009 | EP1819332B1 Pyrrolopyridine-2-carboxylic acid amides |
| 03/11/2009 | EP1786400B1 Pharmaceutical compositions for controlled release delivery of biologically active compounds |
| 03/11/2009 | EP1759199A4 Insulin-independent, bone morphogenetic protein (bmp)-mediated uptake of blood glucose by peripheral cells and tissues |
| 03/11/2009 | EP1691824B1 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients |
| 03/11/2009 | EP1636593B1 Modulating the interaction between hgf beta chain and c-met |
| 03/11/2009 | EP1635776B9 Lipidic protein-transfer systems and cosmetic/dermatological use thereof |
| 03/11/2009 | EP1613294B1 Peptides and derivatives thereof as inhibitors of oxidative damage of the skin |
| 03/11/2009 | EP1611898B9 Composition for the prevention and treatment of cellulitis |
| 03/11/2009 | EP1517919B1 Marked peptides having affinity for a phospholipid and uses |
| 03/11/2009 | EP1468085B1 Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis |
| 03/11/2009 | EP1460992B1 Stabilized reverse micelle compositions and uses thereof |
| 03/11/2009 | EP1429845B1 Treatment or prophylaxis of insulin-producing cell graft rejection |
| 03/11/2009 | EP1379550B1 A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences |
| 03/11/2009 | EP1325127B1 Method for the production of vitamin k-dependent proteins |
| 03/11/2009 | EP1305409B1 Renal regulatory elements and methods of use thereof |
| 03/11/2009 | EP1302476B1 Reduced fk228 and use thereof |
| 03/11/2009 | EP1221985B1 Conveyance of anti-infective activity to wound dressings |
| 03/11/2009 | EP1173567B1 Tribonectins |
| 03/11/2009 | EP1135094B1 Method to reduce hair loss and stimulate hair regrowth |
| 03/11/2009 | EP0988374B1 Hydrophilic composition containing protease produced by vibrio proteolyticus |
| 03/11/2009 | EP0977579B1 Gastrin receptor-avid peptide conjugates |
| 03/11/2009 | EP0741784B1 Ligand (act-4-l) to a receptor on the surface of activated cd4+ t-cells |
| 03/11/2009 | CN101384716A Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same |
| 03/11/2009 | CN101384709A Anti-inflammatory peptides |
| 03/11/2009 | CN101384622A FGF2-binding peptides and uses thereof |
| 03/11/2009 | CN101384620A method of improving efficacy of biological response-modifying proteins and the exemplary muteins |
| 03/11/2009 | CN101384617A Multimeric complexes of antigens and an adjuvant |
| 03/11/2009 | CN101384613A Novel antimicrobial peptides and use thereof |
| 03/11/2009 | CN101384277A Novel anticancer cathepsin preparation and anticancer agent for combination therapy against cancer using the same |
| 03/11/2009 | CN101384276A Method for preparing insulin preparation for oral using |
| 03/11/2009 | CN101384275A Dissolution aids for oral peptide delivery comprising a biguanide |
| 03/11/2009 | CN101384274A Compositions containing peptides with non-natural amino acids and methods of use |
| 03/11/2009 | CN101384273A Microrna expression abnormalities in pancreatic endocrine and acinar tumors |
| 03/11/2009 | CN101384272A Methods and compositions for delivering active agents with enhanced pharmacological properties |
| 03/11/2009 | CN101381757A Solid fermentation preparation method of antibacterial peptide and application |
| 03/11/2009 | CN101381742A Late promoter targeting regulation oncolytic adenovirus pCN305 vector and construction method and application thereof |
| 03/11/2009 | CN101381414A Ovarian cancer anti-idiotype antibody and preparation of heat shock protein fusion protein and application |
| 03/11/2009 | CN101381413A Modified recombinant human endostatin and use thereof |